Arevirumab
Arevirumab (Arevirumab-3) is a pan-lineage neutralizing human monoclonal antibody cocktail (8.9F, 12.1F, 37.D). Arevirumab protects cynomolgus monkeys from severe Lassa fever caused by lineage II and III LASV isolates. Arevirumab is applicable to research related to Lassa fever.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG1 kappa
Lassa virus
Arevirumab-3 (15 mg/kg of each monoclonal antibody in the cocktail; i.v.; days 8, 11, and 14 post-challenge) provides 100% survival to cynomolgus macaques with advanced Lassa fever caused by LASV lineage III strain Ojoko, and significantly reduces viral loads in circulation and tissues[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Macaca fascicularis (healthy adult, Asian origin, male and female, age ~4 to 5.5 y, weight 3.0 to 5.2 kg)[1]
-
Dosage:15 mg/kg of each monoclonal antibody (8.9F, 12.1F, 37.2D) in the Arevirumab-3 cocktail
-
Administration:i.v.; days 8, 11, and 14 post-challenge
-
Result:Ensured 100% survival of all 5 treated macaques at study end.
Cleared infectious LASV from circulation by day 11 post-challenge in all treated animals.
Eliminated circulating viral genomic RNA (vRNA) in all treated animals by day 21 post-challenge.
Reduced tissue vRNA levels significantly compared to untreated control (multiplicity-adjusted P ≤ 0.020 for all assayed tissues).
Caused a significant difference in peak viremia (measured by both vRNA and infectious virus) between treated animals and control cohorts (P = 0.004 and P = 0.007, respectively).
-
Animal Model:Macaca fascicularis (healthy adult, Asian origin, male and female, age ~3 to 7 y, weight 3.0 to 5.4 kg)[1]
-
Dosage:15 mg/kg of each monoclonal antibody (8.9F, 12.1F, 37.2D) in the Arevirumab-3 cocktail
-
Administration:i.v.; days 8, 11, and 14 post-challenge
-
Result:Ensured 100% survival of all 5 treated macaques at study end.
Cleared infectious LASV from circulation by day 14 post-challenge in all treated animals.
Eliminated circulating vRNA in all treated animals by day 14 post-challenge.
Reduced tissue vRNA levels significantly compared to untreated control (multiplicity-adjusted P ≤ 0.031 for most assayed tissues).
Caused a significant difference in peak vRNA load between the Arevirumab-3 cohort and controls (multiplicity-adjusted P = 0.027).
GPC
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[Arevirumab]
-
Synonyms
Arevirumab-3
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz